NORDICUS PARTNERS CORPORATION ENTERS INTO A CONSULTANCY AGREEMENT WITH OROCIDIN A/S IN DENMARK

Beverly Hills, California., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTC PINK: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a paying Consultancy Agreement with Orocidin A/S in Denmark.

Orocidin A/S (“Orocidin”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the preferred treatment against aggressive periodontitis.

Henrik Rouf, CEO of Nordicus, said, “We are pleased that Orodicin chose Nordicus as their exclusive consulting partners to assist with getting established on the U.S. marketplace and becoming Nordicus’ first revenue generating customer. As Orocidin advances in its development of drugs against periodontitis, Nordicus might further consider taking a significant equity stake in Orodicin”.

Allan Wehnert, CEO of Orocidin, added “Our QR-01 product holds huge potential to become a future treatment of periodontitis. Our innovative product is based on a unique polypeptide which mission is to develop the preferred treatment against aggressive periodontitis.

“Our goal is to improve the treatment of periodontitis, reduce the deficiency or disruption of QR-01 in patients with aggressive periodontitis by improving maintenance treatment of periodontitis and reducing treatment relapse. We aim to develop a product that can replace or reduce the need for antibiotics and prevent progression of periodontitis.

“We believe that our innovative therapeutic agent, QR-01, has a unique ability to provide treatment without exacerbating the pressing concern of antibiotic resistance, and that QR-01 promotes inflammation and immune response to fight against infections inflammation, while inhibiting inflammation and preventing tissue damage and chronic diseases. This target product profile outlines the development rationale, treatment modalities, and key features of a subgingival QR-01 antimicrobial peptide formulation for the treatment of periodontitis, reflecting the latest scientific findings in the field.”